AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

GlaxoSmithKline Biologicals, Rixensart, Belgium.
The Journal of Immunology (Impact Factor: 5.36). 11/2009; 183(10):6186-97. DOI: 10.4049/jimmunol.0901474
Source: PubMed

ABSTRACT Adjuvant System 04 (AS04) combines the TLR4 agonist MPL (3-O-desacyl-4'-monophosphoryl lipid A) and aluminum salt. It is a new generation TLR-based adjuvant licensed for use in human vaccines. One of these vaccines, the human papillomavirus (HPV) vaccine Cervarix, is used in this study to elucidate the mechanism of action of AS04 in human cells and in mice. The adjuvant activity of AS04 was found to be strictly dependent on AS04 and the HPV Ags being injected at the same i.m. site within 24 h of each other. During this period, AS04 transiently induced local NF-kappaB activity and cytokine production. This led to an increased number of activated Ag-loaded dendritic cells and monocytes in the lymph node draining the injection site, which further increased the activation of Ag-specific T cells. AS04 was also found to directly stimulate those APCs in vitro but not directly stimulate CD4(+) T or B lymphocytes. These AS04-induced innate responses were primarily due to MPL. Aluminum salt appeared not to synergize with or inhibit MPL, but rather it prolonged the cytokine responses to MPL at the injection site. Altogether these results support a model in which the addition of MPL to aluminum salt enhances the vaccine response by rapidly triggering a local cytokine response leading to an optimal activation of APCs. The transient and confined nature of these responses provides further supporting evidence for the favorable safety profile of AS04 adjuvanted vaccines.

Download full-text


Available from: Daniel Larocque, Sep 02, 2015
  • Source
    • "TLR signaling and the resulting innate and adaptive responses can be enhanced by synergy within the TLR family [15] or by signals from TLR combined with those from non-TLR innate sensors [16,17]. Within the TLR family, TLR4 and TLR7 have been targeted by agonists that are in late stage development [18,19] or are commercial [20,21] and the two TLR show potential for powerful synergism. This can be seen in increased magnitudes of cytokine secretion, enhanced germinal center formation, class switching and antibody diversity [22,23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent reports that TLR4 and TLR7 ligands can synergistically trigger Th1 biased immune responses suggest that an adjuvant that contains both ligands would be an excellent candidate for co-administration with vaccine antigens for which heavily Th1 biased responses are desired. Ligands of each of these TLRs generally have disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle. We show here that the TLR7 ligand, imiquimod, and the TLR4 ligand, GLA, synergistically trigger responses in human whole blood. We combined these ligands in an anionic liposomal formulation where the TLR7 ligand is in the interior of the liposome and the TLR4 ligand intercalates into the lipid bilayer. The new liposomal formulations are stable for at least a year and have an attractive average particle size of around 140 nm allowing sterile filtration. The synergistic adjuvant biases away from Th2 responses, as seen by significantly reduced IL-5 and enhanced interferon gamma production upon antigen-specific stimulation of cells from immunized mice, than any of the liposomal formulations with only one TLR agonist. Qualitative alterations in antibody responses in mice demonstrate that the adjuvant enhances Th1 adaptive immune responses above any adjuvant containing only a single TLR ligand as well. We now have a manufacturable, synergistic TLR4/TLR7 adjuvant that is made with excipients and agonists that are pharmaceutically acceptable and will have a straightforward path into human clinical trials.
    Journal of Nanobiotechnology 04/2014; 12(1):17. DOI:10.1186/1477-3155-12-17 · 4.08 Impact Factor
  • Source
    • "[3]–[5] However, effective cancer immunotherapies require Th1 cytokines to arrest tumor growth, specifically interferon (IFN)-γ and tumor necrosis factor (TNF)-α. [6] To overcome this deficiency, a novel formulation containing alum and the Toll-like receptor (TLR)-4 ligand monophosphoryl lipid A (MPL) has been used to enhance adaptive immunity. [7] MPL, which is approved for clinical use in vaccines, induces secretion of IL-12 by antigen presenting cells (APC), leading to IFN-γ secretion by T and NK cells [8], [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Porous silicon (pSi) microparticles, in diverse sizes and shapes, can be functionalized to present pathogen-associated molecular patterns that activate dendritic cells. Intraperitoneal injection of MPL-adsorbed pSi microparticles, in contrast to free MPL, resulted in the induction of local inflammation, reflected in the recruitment of neutrophils, eosinophils and proinflammatory monocytes, and the depletion of resident macrophages and mast cells at the injection site. Injection of microparticle-bound MPL resulted in enhanced secretion of the T helper 1 associated cytokines IFN-γ and TNF-α by peritoneal exudate and lymph node cells in response to secondary stimuli while decreasing the anti-inflammatory cytokine IL-10. MPL-pSi microparticles independently exhibited anti-tumor effects and enhanced tumor suppression by low dose doxorubicin nanoliposomes. Intravascular injection of the MPL-bound microparticles increased serum IL-1β levels, which was blocked by the IL-1 receptor antagonist Anakinra. The microparticles also potentiated tumor infiltration by dendritic cells, cytotoxic T lymphocytes, and F4/80+ macrophages, however, a specific reduction was observed in CD204+ macrophages.
    PLoS ONE 04/2014; 9(4):e94703. DOI:10.1371/journal.pone.0094703 · 3.23 Impact Factor
  • Source
    • "Monophosphoryl lipid A (MPL) is a non-toxic derivative of LPS isolated from Salmonella minnesota rough strain. MPL, in combination with aluminum salt, has been approved for use as an adjuvant for hepatitis B virus (HBV) and human papillomavirus (HPV) vaccines [4], [5]. Several other synthetic structural analogs of lipid A have been prepared to obtain TLR4 agonists with reduced toxicity [6], [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipopolysaccharide (LPS) is a major component of the outer membrane of Gram-negative bacteria. LPS elicits strong immunopathological responses during bacterial infection, and the lipid A moiety of LPS is responsible for this immunostimulatory activity. Lipid A exerts its biological activity by sending signals via TLR4 present on immune cells, and TLR4 agonists have been a target for vaccine adjuvant. Previously, we demonstrated an adjuvant activity of deacylated lipooligosaccharide (dLOS) to viral and bacterial antigens. In this study, we characterized the chemical structure of dLOS and evaluated its immunostimulatory activity on mouse and human immune cells in comparison with monophosphoryl lipid A (MPL). dLOS consists of a core oligosaccharide lacking the terminal glucose residue, a glucosamine disaccharide with two phosphate groups, and two N-linked acyl groups. dLOS was similar to MPL in induction of cytokine production in mouse peritoneal macrophages, but was a more potent activator in human monocytes and dendritic cells (DCs). Results of an analysis of allogeneic T cell responses revealed that dLOS induces Th1, Th2, and Th17-type immune responses in a dose-dependent manner. The immunostimulatory activities of dLOS were completely abrogated in TLR4(-/-) mice, which confirms its TLR4-dependency. These results suggest that in the presence of the core oligosaccharide, O-linked acyl groups of LPS are dispensable for activating the TLR4 signaling pathway. dLOS did not cause any pathological effects or death at 0.25, 0.5, or 1 mg per kg body weight in mice in the acute toxicity tests. This result suggests that dLOS has a low toxicity. dLOS should be considered for further development as a safe and effective adjuvant for human vaccines.
    PLoS ONE 01/2014; 9(1):e85838. DOI:10.1371/journal.pone.0085838 · 3.23 Impact Factor
Show more